Topics enriched in Samples 4 and 16 include genes such as AR, GRHL2, FOXA1, SLC43A1, WNT7B, which are known downstream players active in prostate cancers with ERG expression49,50. This evidence concerns the gene SLC43A1 and prostate carcinoma.